Abstract: Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention or amelioration of a disease, condition or disorder through inhibition of the complement alternative pathway.

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.

Abstract: A reusable menstrual discharge collection device is described comprising: dual durometer article that forms a menstrual discharge disc-shaped collection device with a half spherical dome catch where the half spherical dome catch includes a continuous circumferential top and bottom portion, and wherein the continuous top portion is attached to a continuous uniform flexible hinge that is placed along an entire circumferential uniform upper portion of the half spherical dome catch and wherein the hinge also forms a base for and is connected to a 360-degree continuous uniform circumferential rim section such that the hinge allows the half spherical dome catch to be in both an inverted use position/configuration that allows movement of the catch toward the rim section allowing for adjustability to fit multiple cervix physiologies and the elongated configuration allows for ease of manufacturing and cleaning.

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: A reusable menstrual discharge collection device is described comprising: dual durometer article that forms a menstrual discharge disc-shaped collection device with a half spherical dome catch where the half spherical dome catch includes a continuous circumferential top and bottom portion, and wherein the continuous top portion is attached to a continuous uniform flexible hinge that is placed along an entire circumferential uniform upper portion of the half spherical dome catch and wherein the hinge also forms a base for and is connected to a 360-degree continuous uniform circumferential rim section such that the hinge allows the half spherical dome catch to be in both an inverted use position/configuration that allows movement of the catch toward the rim section allowing for adjustability to fit multiple cervix physiologies and the elongated configuration allows for ease of manufacturing and cleaning.

Abstract: Provided herein are systems and methods for generating fetal cardiac magnetic resonance (MR) images of a living fetus, within a uterus of a parent of the fetus, by imaging the fetus within the uterus using a magnetic resonance imaging (MRI) system. Also provided herein are methods for deriving information indicative of fetal cardiac cycles from MR data obtained by an MRI system while imaging the fetus, the MR data including MR data for the center of k-space. The derived information may be used to differentiate the fetal cardiac cycles from other sources of noise in the MR data such as the parental cardiac cycles.

Abstract: Provided herein are compounds, compositions and methods useful for inhibiting lactate dehydrogenase (LDH) activity and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to LDH activity, or the accumulation of oxalate, including hyperoxaluria.

Abstract: A reusable menstrual discharge collection device is described comprising: a continuous single piece article that forms a menstrual discharge disc-shaped collection device with a half spherical dome catch where the half spherical dome catch includes a continuous top and bottom portion, and wherein the continuous top portion is attached to a continuous flexible hinge that is placed along an entire circumferential upper portion of the half spherical dome catch and wherein the hinge also forms a base for and is connected to a 360 degree continuous rim section such that the hinge allows the continuous rim section to be in both an inverted use position/configuration that allows movement of the rim section toward the half dome spherical catch allowing for adjustability to fit multiple cervix physiologies and the elongated configuration that allows for ease of manufacturing and cleaning.

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: A reusable menstrual discharge collection device is described comprising: a continuous single piece article that forms a menstrual discharge disc-shaped collection device with a half spherical dome catch where the half spherical dome catch includes a continuous top and bottom portion, and wherein the continuous top portion is attached to a continuous flexible hinge that is placed along an entire circumferential upper portion of the half spherical dome catch and wherein the hinge also forms a base for and is connected to a 360 degree continuous rim section such that the hinge allows the continuous rim section to be in both an inverted use position/configuration that allows movement of the rim section toward the half dome spherical catch allowing for adjustability to fit multiple cervix physiologies and the elongated configuration that allows for ease of manufacturing and cleaning.

Abstract: The disclosure relates to a clamping device and method of securing a clamping device. The clamping device is suitable for clamping an elongate member, and includes a body portion for surrounding the elongate element and configured to apply a compressive force on the elongate member. The body portion includes at least two outwardly curved plates.

Abstract: Provided herein are compounds for the treatment or prevention of AMPK-(5? adenosine monophosphate-activated protein kinase) mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: This invention is directed to novel heterocyclic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.

Abstract: This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., (s) controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.

Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.

Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.

Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.